
Quarterly report 2026-Q1
added 05-14-2026
Autolus Therapeutics plc Net Debt 2011-2026 | AUTL
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Autolus Therapeutics plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.7 M | -175 M | -187 M | -358 M | - | - | - | - | -137 M | -27.9 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -27.9 M | -358 M | -153 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-16.8 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-7.39 M | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 16.93 | -2.14 % | $ 791 M | ||
|
AgeX Therapeutics
AGE
|
71 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
-3.91 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-206 M | $ 7.45 | -4.85 % | $ 204 M | ||
|
Athira Pharma
ATHA
|
-68.5 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
52 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
-17 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 4.09 | -7.16 % | $ 1.22 B | ||
|
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.57 | -3.68 % | $ 184 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
BioNTech SE
BNTX
|
-7.45 B | $ 89.73 | -2.46 % | $ 21.7 B | ||
|
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | - | - | $ 231 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-5.46 M | $ 3.38 | -3.15 % | $ 5.56 M | ||
|
Aeterna Zentaris
AEZS
|
-5.16 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-7.29 M | $ 0.73 | -0.15 % | $ 33.4 M | ||
|
Eton Pharmaceuticals
ETON
|
-4.11 M | $ 29.89 | -0.23 % | $ 804 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Esperion Therapeutics
ESPR
|
-165 M | $ 3.13 | 0.16 % | $ 651 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Exelixis
EXEL
|
-282 M | $ 50.21 | -1.74 % | $ 13.6 B | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
-96.6 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 21.61 | 0.19 % | $ 2.75 B | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Fortress Biotech
FBIO
|
-24.8 M | $ 2.42 | 5.0 % | $ 67.5 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Forte Biosciences
FBRX
|
-58.8 M | $ 22.57 | -5.8 % | $ 292 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Fennec Pharmaceuticals
FENC
|
-7.29 M | $ 9.66 | 4.6 % | $ 276 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M |